Ben Westphalen
@BenWestphalen
Oncologist focused on #PrecisionOncology 🎯 & #PancreaticCancer 💜 •@myesmo PMWG chair • #MissionCancer Board🇪🇺•Rolling with @OncoAlert 🚨 •Views are my own•
ID:529391306
http://linkedin.com/in/benedikt-westphalen-01137514b 19-03-2012 13:43:11
9,5K Tweets
4,3K Followers
200 Following
Follow People
Vivek Subbiah, MD
Chief, Early-Phase Drug Development|@SarahCannonDocs #Oncologist, #Phase1trials, #PrecisionMedicine. Tweets=My own.
Paolo Tarantino
Medical Oncologist, Research Fellow @DanaFarber | @Harvard | PhD @LaStatale. SoMe Editor @ESMO_Open. Interested in breast oncology, HER2, ADCs & good music.
Myriam Chalabi
Medical Oncologist, GI cancers @nki_nl neoadjuvant #immunotherapy #cancerresearch. Opinions my own
Matteo Lambertini, MD PhD
Associate Professor at @UniGenova & Medical Oncologist at @SanMartino_Ge. Chair of @myESMO YOC. #BreastCancer #Fertility. Big fan of @sampdoria & @giroditalia.
Arndt Vogel
Clinician-scientist, focused on liver cancer & precision oncology, Toronto General Hospital/Princess Margaret Cancer Center 🇨🇦/MHH🇩🇪
#Cancer #Genomics play an integral part in our understanding of of malignant diseases. Yet, #ethnic #diversity in #Cancer Research is lacking behind.
Important manuscript in JCO Precision Oncology highlighting this critical issue.
#PrecisionMedicine OncoAlert 🚨
ascopubs.org/doi/10.1200/PO…
First ESMO - Eur. Oncology Virtual Journal Club on May 22 at 630pm (CEST) - pencil down your agendas! Important data to be discussed by experts George Pentheroudakis FabriceAndre Solange Peters Andres Cervantes
esmo.org/about-esmo-mee…
#OpenAccess #ResearchPaper in npj Journals #PrecisionOncology 👇🏼
Data from 3499 #PancreaticCancer samples shows distinct molecular & immune profiles in head vs. body/tail #cancers
#pancsm 💜 OncoAlert 🚨 Aatur Singhi, MD PhD KenOliveLab
nature.com/articles/s4169…
This is important👇🏼
The #EUMissions provide extensive funding to help addressing the most pressing problems of our time!
🚨Just in 👉🏼FDA grants accelerated approval to tovorafenib for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma
✅First targeted therapy approved for BRAF fusions. #PrecisionMedicine for the win🎯🧬OncoDaily OncoAlert OncLive.com
Link to approval.…
Phase I TROPION-PanTumor01 Study
✅Dato-DXd💊Shows promising efficacy and manageable safety in heavily pretreated🧬 HR+/HER2– #BreastCancer and #TNBC patients
➡️suggesting potential for advancement to phase III studies‼️
Aditya Bardia, MD
Ian E. Krop Dana-Farber…
Thank you Heather Hampel for your positive opinion on our paper and for recommending it. We really hope it can be of benefit for many colleagues
CA: A Cancer Journal for Clinicians
Ben Westphalen Umberto Malapelle Vivek Subbiah, MD Clare Turnbull- Prof/NHS Dr Debyani Chakravarty, PhD 🇺🇦 Nicola Normanno Melissa B Davis, PhD
⭐️Fantastic overview of #MolecularTumorBoards -MTB 101 & in depth thought provoking lecture - by the amazing Ben Westphalen at the Italian summit for precision 💊 medicine!
What are MTB’s? Panel of multi-D expert who review molecular-profiling results & match to available…
The 2020 paper by Fernanda Mosele & FabriceAndre on the use of NGS in advanced #Cancer is a landmark in #PrecisionMedicine ⭐️
Now there is an update in press in Annals of Oncology & we get a sneak peek during todays 🇮🇹 #precisionmedicine summit 🤩
#PrecisionMedicine OncoAlert 🚨
#openaccess ESMO - Eur. Oncology ESMO Open genomic profiling in the management of #patients w rare #cancers :
Rare cancer patients show favourable response to matched therapies, with a higher ORR in early treatment lines.
#PrecisionMedicine OncoAlert 🚨
esmoopen.com/article/S2059-…
Going beyond Cancer with T cell engagers: First-in-human report on a CD19 TCE for safe & successful treatment in systemic sclerosis. EJC in press. Oncology Advance
Watch out for European Journal of #Cancer #Researchpaper out Monday describing a case of refractory systemic sclerosis successfully treated w a CD19/CD3 T cell engager
#precisionmedicine OncoAlert 🚨
Vivek Subbiah, MD MariSubklewe Michael von Bergwelt LMU Klinikum München Hämatologie und Onkologie
linkedin.com/feed/update/ur…
Buckle up…we are in for a ride…
Vivek Subbiah, MD on the principles of #tumour agnostic drug development.
#PrecisionMedicine
Funding alert 🚨
New European Commission Horizon Europe🇪🇺 #MissionCancer funding opportunities published:
These calls vary in their objectives, from improving diagnostic techniques and treatment methods to enhancing preventive measures and patient care systems.
ec.europa.eu/info/funding-t…
In Nature Medicine ➡️ How to implement risk-based #lcsm screening in a universal healthcare system; results of a pilot program in #Ontario 🇨🇦
Screening detected 2.4% #cancers w 79.2% early-stage w 95.5% specificity 🎯
nature.com/articles/s4159…
#PrecisionMedicine OncoAlert 🚨
What about surrogate end points in clinical trials? Fantastic talk by Dario Trapani at the Italian Summit in #PrecisionMedicine including the slide on correlation vs causation
⭐️Terrific overview of using each patient as own control to assess the efficacy of drugs in small patient populations by Dr. Christophe Le Tourneau - PI of the SHIVA trial. at the Italian Summit on #PrecisionMedicine G Curigliano MD PhD Ben Westphalen Dario Trapani
How are we are going to run #clinicaltrials in the future?
Can #patients serve as there own control in settings in which randomization is not possible and/or unethical…
Brilliant talk by #precisiononcology super ⭐️ Christophe Le Tourneau of Institut Curie Vivek Subbiah, MD
Such a pleasure to catch up with so many inspiring colleagues that became friends over the years.
Grateful to G Curigliano MD PhD and Paolo Marchetti for putting this world class faculty together!